Omeros | OMER - Debt


Omeros reported $442.16M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Adma Biologics USD 204.41M 121.28M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 725.8M 1.82M Jun/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 63.19B 536M Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026